Results for tag: "Zykadia"

Zykadia (ceritinib) is a targeted therapy drug used to treat non-small cell lung cancer (NSCLC). It is a type of kinase inhibitor, which works by blocking certain proteins that help cancer cells grow and divide. Zykadia is approved for use in patients with ALK-positive NSCLC, which is a type of lung cancer caused by a gene mutation. It is also approved for use in patients with ROS1-positive NSCLC, which is another type of lung cancer caused by a gene mutation. Zykadia is taken orally, usually once a day, and is available in capsule and tablet form. The Zykadia market is a rapidly growing segment of the lung cancer drug market. It is a highly competitive market, with several companies offering similar products. Companies in the Zykadia market include Novartis, Pfizer, AstraZeneca, and Daiichi Sankyo. These companies are all actively researching and developing new treatments for lung cancer, and are working to improve the efficacy and safety of existing treatments. Show Less Read more